INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE
INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING
INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE
Buvidal is indicated for:
- Treatment of opioid dependence within a framework of medical, social and psychological treatment.
- Treatment is intended for use in adults and adolescents aged 16 years or over.
Administration of Buvidal is restricted to healthcare professionals.
Appropriate precautions, such as to conduct patient follow-up visits with clinical monitoring according to the patient’s needs, should be taken when prescribing and dispensing buprenorphine. Take-home use or self-administration of the product by patients is not allowed.
Buvidal can be administered as either a weekly or a monthly injection.
Buvidal is available in the following doses:
For weekly injection:
For monthly injection:
Pre-filled syringes containing Buvidal 64 mg (0.18ml), 96 mg (0.27ml), 128 mg (0.36ml) and 160 mg (0.45ml) prolonged-release solution for injection.